Abstract
Aims: A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m 2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan. Materials & methods: DNA was isolated from 85 advanced cancer patients treated with 300 or 350 mg/m2 irinotecan and genotyped for haplotype-tag polymorphisms across TOP1, PARP1, TDP1 and XRCC1. Associations between genotypes and haplotypes and log(absolute neutrophil count nadirs) were assessed by linear regression. Results: No associations were observed. Conclusion: Our findings suggest that the genes we tested do not influence toxicity of irinotecan when adminstered at 300-350 mg/m2.
Original language | English (US) |
---|---|
Pages (from-to) | 1139-1146 |
Number of pages | 8 |
Journal | Pharmacogenomics |
Volume | 10 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2009 |
Externally published | Yes |
Keywords
- Irinotecan
- PARP1
- Pharmacogenetics
- TDP1
- TOP1
- XRCC1
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Pharmacology